Source comparison
MK-677 Side Effects: Research vs Anecdotal Claims
Comparing documented clinical trial data to anecdotal reports reveals where evidence supports claims and where it doesn't. This distinction matters for research design. Building a protocol around unsubstantiated side effects wastes resources and compromises ou
This comparison does not assign a generated winner or score.
- Comparing documented clinical trial data to anecdotal reports reveals where evidence supports claims and where it doesn't. This distinction matters for research design. Building a protocol around unsubstantiated side effects wastes resources and compromises outcomes.
- Elevated fasting glucose
- Documented in multiple RCTs; 7–12 mg/dL increase at 25mg daily
- 2–4 weeks
- GH counter-regulatory effect on insulin signaling
- Monitor weekly during month one; contraindicated if baseline fasting glucose >100 mg/dL
- Increased appetite
- Reported by >80% of trial participants
- 48–72 hours
- Direct ghrelin receptor agonism
- Predictable and persistent; requires caloric intake control in body composition studies
- Lower extremity edema
- 15–25% incidence in clinical trials
- 1–2 weeks
- Aldosterone-driven sodium retention
- Typically resolves by week 6–8; persistent edema warrants discontinuation
- Cortisol elevation
- 15–30% above baseline in pharmacokinetic studies
- 2–4 hours post-dose
- ACTH stimulation from pituitary
- Monitor morning fasting cortisol if protocol exceeds 12 weeks
- Prolactin increase
- Documented but inconsistent; 20–50% increase when present
- Hypothalamic dopamine modulation
- Measure at baseline and week 4; discontinue if >25 ng/mL (males) or symptomatic
- Lethargy or fatigue
- Reported anecdotally; not consistently documented in trials
- Variable
- Possibly related to insulin resistance or cortisol
- Correlate with glucose and cortisol markers; may indicate metabolic intolerance
- Joint pain
- Rare in MK-677 studies; more common with exogenous GH
- Not established
- Not consistent with secretagogue mechanism
- Likely confounded by other compounds or pre-existing conditions
- The table clarifies which effects are mechanism-driven and predictable versus which are anecdotal without controlled trial support. Joint pain, for example, is commonly cited in community discussions but rarely appears in clinical literature at secretagogue doses. It's a well-documented consequence of supraphysiological exogenous GH administration (where GH levels exceed 10–15 ng/mL sustained), but MK-677 produces pulsatile GH release that peaks at 5–8 ng/mL and returns to baseline between pulses. A physiological pattern that doesn't typically cause the fluid-driven carpal tunnel compression or joint swelling seen with GH injections.